Purpose/Objectives: To evaluate the intermediate term efficacy and toxicity of the use of venlafaxine for the control of hot flashes.
Design: An open-label continuation phase study following a double-blind, randomized, placebo-controlled clinical trial that tested three doses of venlafaxine for the control of hot flashes.
Setting: North Central Cancer Treatment Group institutions.
Sample: 102 postmenopausal women.
Methods: Women could titrate venlafaxine to optimum efficacy while recording daily hot flash counts and weekly toxicity information.
Main Research Variables: Hot flash frequency, hot flash score.
Findings: The reduction in hot flashes previously reported in the randomized study phase was maintained during the open-label study. Toxicity did not appear to increase over time.
Conclusions: The data from this study provides evidence that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes.
Implications for Nursing Practice: Nurses can inform symptomatic women that an effective nonhormonal alternative exists to control their hot flashes.
Barton, D.L., Loprinzi, C.L., Quella, S.K., Sloan, J.A., Veeder, M.H., Egner, J.R., Stella, P.J., Swan, D.K., Vaught, N.L., & Novotny, P. (1998). Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Journal of Clinical Oncology, 16, 155-158.
Beck, A.T., Steer, R.A., & Garbin, M.G. (1998). Psychometric properties of the Beck depression inventory: Twenty-five years of evaluation. Clinical Psychological Review, 8, 77-100.
Bergmans, M., Merkus, J., Corbey, R., Schelleken, L., & Ubachs, J. (1987). Effect of Bellergal Retard on climacteric complaints: A double-blind, placebo-controlled study. Maturitas, 9, 227-234.
Carpenter, J., & Andrykowski, M. (1999). Menopausal symptoms in breast cancer survivors. Oncology Nursing Forum, 26, 1311-1317.
Dew, J., Eden, J., Beller, E., Magarey, C., Schwartz, P., Crea, P., & Wren, B. (1998). A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric, 1(1), 137-142.
Fenlon, D. (1995). Menopause: A problem for breast cancer patients. European Journal of Cancer Care, 4, 166-172.
Finck, G., Barton, D.L., Loprinzi, C.L., Quella, S.K., & Sloan, J.A. (1998). Definitions of hot flashes in breast cancer survivors. Journal of Pain and Symptom Management, 16, 327-333.
Goldberg, R.M., Loprinzi, C.L., O'Fallon, J.R., Veeder, M.H., Miser, A.W., Mailliard, J.A., Michalak, J.C., Dose, A.M., Rowland, K.M., Jr., & Burnham, N.L. (1994). Transdermal clonidine for ameliorating tamoxifeninduced hot flashes. Journal of Clinical Oncology, 12, 155-158.
Greendale, G., Lee, N., & Arriola, E. (1999). The menopause. Lancet, 353, 571-580.
Kent, J. (2000). SnaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet, 355, 911-918.
Kronenberg, F. (1990). Hot flashes: Epidemiology and physiology. In M. Flint, F. Kronenberg, and W. Utian (Eds.), Multidisciplinary perspectives on menopause (pp. 52-86). New York: New York Academy of Sciences.
Loprinzi, C.L., Kugler, J.W., Sloan, J.A., Mailliard, J.A., La Vasseur, B.I., Barton, D.L., Novotny, P.J., Dakhil, S.R., Rodger, K., Rummans, T.A., & Christensen, B.J. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: A randomized controlled trial. Lancet, 356, 2059-2063.
Loprinzi, C.L., Michalak, J.C., Quella, S.K., O'Fallon, J.R., Hatfield, A.K., Nelimark, R.A., Dose, A.M., Fischer, T., Johnson, C., Klatt, N.E., Bate, W.W., Rospond, R.M., & Oesterling, J.E. (1994). Megesterol acetate for the prevention of hot flashes. New England Journal of Medicine, 331, 347-352.
Loprinzi, C.L., Pisansky, T.M., Fonseca, R., Sloan, J.A., Zahasky, K.M., Quella, S.K., Novotny, P.J., Rummans, T.A., Dumesic, D.A., & Perez, E.A. (1998). Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. Journal of Clinical Oncology, 16, 2377-2381.
Maunsell, E., Allard, P., Dorval, M., & Labbe, J. (2000). A brief pain diary for ambulatory patients with advanced cancer: Acceptability and validity. Cancer, 88, 2387-2397.
Pandya, K., Raubertas, R., Flynn, P., Hynes, H., Rosenbluth, R., Kirshner, J., Pierce, I., Dragalin, V., & Morrow, G. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center community clinical oncology program study. Annals of Internal Medicine, 132, 788-793.
Sherliker, L., & Steptoe, A. (2000). Coping with new treatments for cancer: A feasibility study of daily diary measures. Patient Education and Counseling, 40(1), 11-19.
Sloan, J.A., Loprinzi, C.L., Kuross, S.A., Miser, A.W., O'Fallon, J.R., Mahoney, M.R., Heid, I.M., Bretscher, M.E., & Vaught, N.L. (1998). Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. Journal of Clinical Oncology, 16, 3662-3673.
Swain, S., Santen, R., Burger, H., & Pritchard, K. (1999). Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Oncology, 56, 859-875.
Treatment of estrogen deficiency symptoms in woman surviving breast cancer. (1998). Journal of Clinical Endocrinology and Metabolism, 83, 1993-2000.
University of California, San Francisco School of Nursing Symptom Management Faculty Group. (1994). A model for symptom management. Image, 26, 272-276.
Weitzner, M.A., Mazzocca, J., Jacobsen, P.B., & Minton, S. (2000). Treatment of hot flashes and fatigue in women with breast cancer: Preliminary findings. Supportive Care in Cancer, 8, 243.